About Zafrens
Zafrens is a company based in San Diego (United States) founded in 2021 by Yi Zhang. Zafrens has raised $29.16 million across 3 funding rounds from investors including imec.xpand, Prime Movers Lab and Kofa Healthcare. The company has 19 employees. Zafrens offers products and services including Z-Screen, Active-seq, and Active-Drug-seq. Zafrens operates in a competitive market with competitors including 10X Genomics, Mission Bio, Singleron, Cellares and LUMICKS, among others.
- Headquarter San Diego, United States
- Employees 19
- Founders Yi Zhang
- SectorsHealthcare
- Email••••••••
- Website zafrens.com
- Social LinkedIn
- Total Equity Funding$29.16M (USD)
in 3 rounds
- Investorsimec.xpand
& 9 more
- Employee Count19
Products & Services of Zafrens
Zafrens offers a comprehensive portfolio of products and services, including Z-Screen, Active-seq, and Active-Drug-seq.
High-throughput platform for cellular assays and sequencing.
Tool for mapping cell states to functional outcomes.
Platform for simultaneous molecular and phenotypic HTS.
Funding Insights of Zafrens
Zafrens has successfully raised a total of $29.16M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.16M
- Total Rounds 3
- First Round $6.16M
(Jan 2022)
- Investors Count 10
All 3 funding rounds of Zafrens with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | – | Series A | – | – | |
| Dec 2023 | $23M | Series A | – | Prime Movers Lab | |
| Jan 2022 | $6.16M | Series A | – | – | – |
10 investors in total: 10 institutional.
Investors in Zafrens
Zafrens has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include imec.xpand, Prime Movers Lab and Kofa Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is invested in early-stage semiconductor and nanotechnology firms. | 2017 | imecxpand.com | Leuven, Belgium | |
Kofa Healthcare is engaged in funding healthcare and biotech innovations. | – | kofahealthcare.com | - | |
Global Brain is recognized as a venture capital firm supporting startups. | – | globalbrains.com | Shibuya, Japan | |
BlueYard Capital is engaged in early-stage technology investments. | 2016 | blueyard.com | United States | |
Early-stage tech-focused VC firm investing primarily in the US | – | foundersxventures.com | Menlo Park, United States | |
Early stage life science startups are supported by investments. | – | alix.vc | - | |
Early-stage investments across multiple sectors are conducted by this firm. | – | possible.ventures | Munich, Germany | |
Venture capital investments are made in healthcare innovation startups. | – | iasoventures.com | Boston, United States | |
Seed stage venture capital investments are made in technology startups. | – | hawktail.com | - | |
Venture capital firm funding breakthrough scientific startups and innovative sectors worldwide. | 2018 | primemoverslab.com | Jackson, United States |
Investor details for Zafrens
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zafrens
8 people are tracked at Zafrens (6 in leadership, 2 in team); the tracked headcount is 19.
| Name | Role | Group |
|---|---|---|
Yi Zhang | Co-Founder & EVP of Engineering | Leadership |
Kandaswamy Vijayan | CEO | Leadership |
Kandaswamy (Swamy) Vijayan | Chief Executive Officer | Leadership |
Steven Brown | Director Of AI | Leadership |
John Ndungu | Senior Director, Chemical Technologies | Leadership |
Allisen Williams | Director Of Operations | Leadership |
Gopi chandran Ravichandran | Senior Scientist, Systems Integration And Process Development | Team |
Alexandre Gillet | Principal Software Engineer | Team |
Complete people profiles for Zafrens
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Zafrens
3 dated milestones of Zafrens across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Zafrens is founded.
- Funding First funding round of $6.2M.
- Funding Latest funding round, Series A,.
Competitors of Zafrens
Zafrens operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Singleron, Cellares and LUMICKS, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| singleron.bio | 2018 | Hagen, Germany | $84.48M | – | Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | |
| cellares.com | 2019 | San Francisco, United States | $355M | – | Medical devices for cell-based therapy manufacturing are produced. | |
| lumicks.com | 2014 | Amsterdam, Netherlands | $93.38M | – | Optical tweezers instruments for single-molecule analysis are manufactured. | |
| levitasbio.com | 2017 | San Francisco, United States | $73.77M | – | Single-cell imaging platform developed via magnetic levitation technology. | |
| rebusbio.com | 2006 | Santa Clara, United States | $20M | – | An imaging system for single-cell gene analysis is developed. | |
| atrandi.com | 2016 | Vilnius, Lithuania | $31.01M | – | Microfluidic solutions for life sciences and single-cell analysis are developed. | |
| xcellbio.com | 2012 | San Francisco, United States | $40.9M | 11 | Cell culture analysis devices for cancer research are developed. |
Detailed competitors of Zafrens
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zafrens
Complete news archive for Zafrens
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Zafrens
10 companies that operate in the same segment as Zafrens (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Zafrens
Zafrens was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Zafrens is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kandaswamy Vijayan is the current CEO of Zafrens.
Zafrens is a funded company, having raised a total of $29.16M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6.16M, raised on Jan 2022.
Zafrens has 19 employees.
Provider of single-cell multi-omics analysis platform for researchers. The company specializes in building tools and generating insights at the interface of biology, chemistry, and engineering. It offers multi-omic assays and the study of mechanistic insights into the RNA regulatory layer.
Zafrens's top competitors include 10X Genomics, Mission Bio and Cellares.
Zafrens offers Z-Screen, Active-seq, and Active-Drug-seq.
Zafrens has 10 investors. Key investors include imec.xpand, Prime Movers Lab, Kofa Healthcare, Global Brain, and BlueYard Capital.